September 13, 2019
MONROE, NY – Innovative Health Sciences LLC (“IHS” or “the Company”) announced today that on September 5, 2019, AML Holdings LLC agreed to invest in the Company through Associate fund and to also partner with the Company to design and manufacture the Company’s medical devices. AML Holdings Limited is a contract manufacturing company (CDMO) with corporate offices located in Hong Kong.
AML Holdings Limited (“AML”), established in 1976 in Hong Kong, owns and operates seven manufacturing facilities throughout the world, specializing in the production of electro-mechanical devices, medical devices, medical plastic, industrial control and home automation, as well as various consumer electronics. In addition to manufacturing, AML also operates a design and engineering facility focused on mechanical and electronic design and software engineering.
“We are so happy to announce this recent partnership with AML Holdings,” says the Company’s President and COO, Dr. Fred Ma, “We are excited to begin the manufacturing process for IHS’ products coming to the market.” The Company’s CEO and product engineer, Andy Sealfon added, “This new technology is what the market has been waiting for. With these devices, we are proud to fill the need of patients around the world.”
Peter Mok, AML’s Vice Chairman, stated, “We are delighted to bring our state-of-the-art manufacturing solutions to the important innovations that IHS is bringing to the home infusion market. We are also happy to have been able to invest in the initial round of financing to support the Company’s growth.”
About Innovative Health Sciences
Innovative Health Sciences, LLC (located in Monroe, NY), is a newly established medical device company focused on developing and commercializing the home infusion device industry using state-of-the-art, proprietary technology, and innovative Intellectual Property (“IP”), with the goal of creating a “one-stop shop” solution for the home infusion industry. IHS intends to optimize the infusion of medications by focusing on patient outcomes and perfecting the science and education of device technologies. IHS is currently developing new infusion technologies for SCIg treatment that will dramatically improve patient outcomes and will re-invent the home infusion therapy business. IHS intends to bridge the gap between infusion medications (Pharma) and infusion systems (Device Manufacturers) through the innovative combination of pharmacokinetics and fluidics.
Forward- Looking Statements
The statements contained herein do not guarantee future performance and undue reliance should not be placed on them. Such Forward Looking Statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied. These statements are based on management’s beliefs and theory. The Company undertakes no obligation to update Forward Looking Statements if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws.
Innovative Health Sciences, LLC